{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:26:56Z","timestamp":1782916016155,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008017","name":"Flinders Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cbi.2021.109401","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T03:21:44Z","timestamp":1612581704000},"page":"109401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite"],"prefix":"10.1016","volume":"338","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-0121","authenticated-orcid":false,"given":"Pramod C.","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1016-1700","authenticated-orcid":false,"given":"Tina B.","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Rawling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2021.109401_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinbiochem.2004.05.006","article-title":"Tyrosine kinase inhibitors in cancer therapy","volume":"37","author":"Madhusudan","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cbi.2021.109401_bib2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","article-title":"Variability of sorafenib toxicity and exposure over time: a pharmacokinetic\/pharmacodynamic analysis","volume":"17","author":"Boudou-Rouquette","year":"2012","journal-title":"Oncol."},{"key":"10.1016\/j.cbi.2021.109401_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics","volume":"57","author":"Lathia","year":"2006","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bcp.2012.04.001","article-title":"Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites","volume":"84","author":"Ghassabian","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.cbi.2021.109401_bib6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","article-title":"Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors","volume":"99","author":"Minami","year":"2008","journal-title":"Canc. Sci."},{"key":"10.1016\/j.cbi.2021.109401_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167906","article-title":"Phase I\/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer","volume":"11","author":"Ferrario","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.cbi.2021.109401_bib8","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2011.34.7427","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia","volume":"29","author":"Inaba","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2021.109401_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ejca.2011.12.026","article-title":"Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours","volume":"48","author":"Awada","year":"2012","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.cbi.2021.109401_bib11","first-page":"5543","article-title":"Selective biotransformation of taxol to 6\u03b1-hydroxytaxol by human cytochrome P450 2C8","volume":"54","author":"Rahman","year":"1994","journal-title":"Canc. Res."},{"key":"10.1016\/j.cbi.2021.109401_bib12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N\u2010demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.113.053793","article-title":"Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug\u2013drug interaction potentials","volume":"42","author":"Wang","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2021.109401_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2021.109401_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-014-0078-5","article-title":"Randomized phase II trial of sorafenib alone or in combination with carboplatin\/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer","volume":"32","author":"Schwandt","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.cbi.2021.109401_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000493951","article-title":"Different chemotherapy regimens in the management of advanced or metastatic urothelial cancer: a bayesian network meta-analysis of randomized controlled trials","volume":"50","author":"Wang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.cbi.2021.109401_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3492-1","article-title":"A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second-and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)","volume":"17","author":"Decker","year":"2017","journal-title":"BMC Canc."},{"key":"10.1016\/j.cbi.2021.109401_bib18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10637-009-9321-x","article-title":"Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non\u2013small cell lung cancer","volume":"28","author":"Okamoto","year":"2010","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.cbi.2021.109401_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/thy.2010.0270","article-title":"Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer","volume":"21","author":"Toubert","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.cbi.2021.109401_bib20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/bjc.2012.312","article-title":"Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer","volume":"107","author":"Nabhan","year":"2012","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.cbi.2021.109401_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.pa.23.040183.002405","article-title":"Suicidal destruction of cytochrome P-450 during oxidative drug metabolism","volume":"23","author":"Ortiz de Montellano","year":"1983","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cbi.2021.109401_bib22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0026-895X(25)13673-0","article-title":"Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion","volume":"43","author":"Butler","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3565(25)22422-3","article-title":"Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6\u03b2-hydroxylation activity by cyclophosphamide and ifosfamide in vitro","volume":"270","author":"Murray","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2021.109401_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17425255.3.1.51","article-title":"Time-dependent CYP inhibition","volume":"3","author":"Riley","year":"2007","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.cbi.2021.109401_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13318-017-0417-y","article-title":"The role of drug metabolites in the inhibition of cytochrome P450 enzymes","volume":"42","author":"Mikov","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.cbi.2021.109401_bib26","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/0006-2952(84)90090-X","article-title":"In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes","volume":"33","author":"Murray","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0003-9861(88)90202-0","article-title":"Complexation of cytochrome P-450 isozymes in hepatic microsomes from SKF 525-A-induced rats","volume":"262","author":"Murray","year":"1988","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cbi.2021.109401_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0026-895X(25)09202-8","article-title":"Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline","volume":"42","author":"Murray","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s13318-016-0385-7","article-title":"Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone","volume":"42","author":"Giri","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.cbi.2021.109401_bib30","first-page":"580","article-title":"Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis","volume":"22","author":"Chen","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2021.109401_bib31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI114003","article-title":"Downregulation of the male-specific hepatic microsomal steroid 16\u03b1-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis","volume":"83","author":"Cantrill","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cbi.2021.109401_bib32","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0022-3565(25)38622-2","article-title":"Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo","volume":"268","author":"von Moltke","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2021.109401_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/FTD.0b013e318197e1bf","article-title":"A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients","volume":"31","author":"Ghassabian","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cbi.2021.109401_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/00498258509045370","article-title":"Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450","volume":"15","author":"Marcus","year":"1985","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cbi.2021.109401_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/carcin\/4.6.703","article-title":"Alterations of microsomal monooxygenase system and carcinogen metabolism by streptozotocin-induced diabetes in rats","volume":"4","author":"Peng","year":"1983","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cbi.2021.109401_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00498258509045007","article-title":"Selective inhibitory interactions of alkoxymethylenedioxybenzenes towards mono-oxygenase activity in rat-hepatic microsomes","volume":"15","author":"Murray","year":"1985","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cbi.2021.109401_bib37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jchromb.2008.10.011","article-title":"A liquid chromatography\/electrospray ionization mass spectrometry (LC\u2013MS\/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples","volume":"875","author":"d'Esposito","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.cbi.2021.109401_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0026-895X(25)10314-3","article-title":"Altered regulation of cytochrome P-450 enzymes in choline-deficient cirrhotic male rat liver: impaired regulation and activity of the male-specific androst-4-ene-3, 17-dione 16\u03b1-hydroxylase, cytochrome P-450UT-A, in hepatic cirrhosis","volume":"31","author":"Murray","year":"1987","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib39","doi-asserted-by":"crossref","first-page":"17227","DOI":"10.1074\/jbc.M802180200","article-title":"Determinants of cytochrome P450 2C8 substrate binding structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid","volume":"283","author":"Schoch","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2021.109401_bib40","doi-asserted-by":"crossref","first-page":"35630","DOI":"10.1074\/jbc.M405427200","article-title":"The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-\u00c5 resolution","volume":"279","author":"Wester","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2021.109401_bib41","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1093\/bioinformatics\/btg362","article-title":"ModLoop: automated modeling of loops in protein structures","volume":"19","author":"Fiser","year":"2003","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cbi.2021.109401_bib42","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","article-title":"Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges","volume":"36","author":"Gasteiger","year":"1980","journal-title":"Tetrahedron"},{"key":"10.1016\/j.cbi.2021.109401_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01593790","article-title":"Restart procedures for the conjugate gradient method","volume":"12","author":"Powell","year":"1977","journal-title":"Math. Program."},{"key":"10.1016\/j.cbi.2021.109401_bib44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/jcc.540100804","article-title":"Validation of the general purpose Tripos 5.2 force field","volume":"10","author":"Clark","year":"1989","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.cbi.2021.109401_bib45","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1021\/jm050040j","article-title":"Parameter estimation for scoring protein-ligand interactions using negative training data","volume":"49","author":"Pham","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2021.109401_bib46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1124\/dmd.118.085167","article-title":"Computational prediction of the site(s) of metabolism and binding modes of protein kinase inhibitors metabolized by CYP3A4","volume":"47","author":"Nair","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2021.109401_bib47","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1074\/jbc.M312516200","article-title":"Structure of human microsomal cytochrome P450 2C8 Evidence for a peripheral fatty acid binding site","volume":"279","author":"Schoch","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2021.109401_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00498250310001636868","article-title":"Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9","volume":"34","author":"Boye","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cbi.2021.109401_bib50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/(SICI)1097-0134(19991101)37:2<204::AID-PROT6>3.0.CO;2-O","article-title":"Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes","volume":"37","author":"Payne","year":"1999","journal-title":"Proteins"},{"key":"10.1016\/j.cbi.2021.109401_bib51","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1021\/bi982161+","article-title":"Enzymatic determinants of the substrate specificity of CYP2C9: role of B\u2018\u2212C loop residues in providing the \u03c0-stacking anchor site for warfarin binding","volume":"38","author":"Haining","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2021.109401_bib52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0003-9861(02)00548-9","article-title":"Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid","volume":"409","author":"Melet","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cbi.2021.109401_bib53","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1124\/mol.59.4.909","article-title":"Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis","volume":"59","author":"Afzelius","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2021.109401_bib54","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1248\/cpb.52.836","article-title":"Characterization of the CYP2C8 active site by homology modeling","volume":"52","author":"Tanaka","year":"2004","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.cbi.2021.109401_bib55","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2021.109401_bib56","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-011-1585-0","article-title":"Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I\/II pharmacokinetic interaction study","volume":"68","author":"Flaherty","year":"2011","journal-title":"Canc. Chemother. Pharmacol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279721000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:01:57Z","timestamp":1757858517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279721000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":54,"alternative-id":["S0009279721000375"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109401","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2021.109401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109401"}}